CRLX101 Plus Bevacizumab in Advanced RCC

NCT01625936 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: CRLX101 (Cerulean)
DRUG: Bevacizumab

Sponsor

Abramson Cancer Center at Penn Medicine